MRSN - NASDAQ
Mersana Therapeutics, Inc.
$29.08
+0.0000%Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotMersana Therapeutics, Inc. Management Team
Mr. Mikhail Papisov Ph.D.
Co-Founder
Dr. Martin H. Huber M.D.
President, Chief Executive Officer & Director
Compensation
$962,075
Dr. Mohan Bala Ph.D.
Senior Vice President & Chief Development Officer
Compensation
$643,850
Dr. Timothy B. Lowinger Ph.D.
Senior Vice President and Chief Science & Technology Officer
Compensation
$664,175
Mr. Chuck Miller
Senior Vice President of Regulatory Affairs
Mr. Brian C. DeSchuytner
Senior Vice President, Chief Financial Officer & Chief Operating Officer
Compensation
$684,500
Ms. Alejandra Veronica Carvajal J.D.
Senior Vice President, Secretary & Chief Legal Officer
Compensation
$623,525
Mr. Ashish Mandelia
Vice President & Chief Accounting Officer
Mersana Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have sold $15K worth of MRSN shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
2.1K
15.47K
-15K
-$15K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Huber Martin H. Jr.
Director, Officer: President, Ceo
$15K
Bala Mohan
Officer: Svp, Chief Development Officer
$762
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $15K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
MRSN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 08, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 11, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 20, 2020 | June 12, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 23, 2019 | June 07, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 27, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.